Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya

Domaine:

healthcare

Type de record:

paper

Créateur:

InzHamMukWer

Éditeur:

Lip

Hôte:

We performed a countrywide assessment of HIV drug resistance among 123 patients with virological failure on second-line antiretroviral therapy (ART) in Kenya. The percentage of patients harbouring intermediate-to-high-level resistance was 27% for lopinavir-ritonavir, 24% for atazanavir-ritonavir and 7% for darunavir-ritonavir, and 25% had complete loss of activity to all available first and secondline drugs. Overall, one in four patients failing second-line ART have completely exhausted available antiretrovirals in Kenya, highlighting the need for increased access to third-line drugs.

Visit

ora.ox.ac.uk

Similaires

HIV drug resistance and third line treatment outcomes in patients failing: Protease Inhibitor based second-line antiretroviral therapy in ZimbabweImpact of HIV Type 1 Subtype on Drug Resistance Mutations in Nigerian Patients Failing First-Line TherapyProtease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South AfricaCharacterization of HIV‐1 drug resistance among patients with failure of second‐line combined antiretroviral therapy in central Ethiopia885. HIV-1 Treatment Failure and Extensive Drug Resistance in Perinatally Infected Children Failing First-Line Antiretroviral Therapy in Western KenyaHIV-1 Viral Load and Resistance in Genital Secretions in Patients Taking Protease-Inhibitor-Based Second-Line Therapy in Africa

HIV drug resistance and third line treatment outcomes in patients failing: Protease Inhibitor based second-line antiretroviral therapy in Zimbabwe

Introduction: We set out to assess the distribution of HIV drug resistance mutations and their risk

Impact of HIV Type 1 Subtype on Drug Resistance Mutations in Nigerian Patients Failing First-Line Therapy

A diverse array of non-subtype B HIV-1 viruses circulates in Africa and dominates the global pandemi

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa

Limited data exist on HIV-1 drug resistance patterns in South Africa following second-line protease-

Characterization of HIV‐1 drug resistance among patients with failure of second‐line combined antiretroviral therapy in central Ethiopia

Abstract Background As a consequence of the improved availability of combined antiretroviral ther

885. HIV-1 Treatment Failure and Extensive Drug Resistance in Perinatally Infected Children Failing First-Line Antiretroviral Therapy in Western Kenya

Abstract Background Understanding drug resi

HIV-1 Viral Load and Resistance in Genital Secretions in Patients Taking Protease-Inhibitor-Based Second-Line Therapy in Africa

Background HIV is transmitted primarily through sexual intercourse, and the ob